文献速递糖尿病

非诺贝特对新诊断1型糖尿病成人和青少年残余β细胞功能的影响:一项随机临床试验

Effect of fenofibrate on residual beta cell function in adults and adolescents with newly diagnosed type 1 diabetes: a randomised clinical trial.
PubMed 文献 · Diabetologia · 2024-10-30

这项2期、安慰剂对照、双盲随机临床试验纳入58例16至40岁新诊断1型糖尿病患者,随机接受非诺贝特160 mg每日口服或安慰剂治疗52周。主要结局为混合餐耐量试验2小时C肽AUC变化,结果显示两组C肽水平、胰岛素用量和血糖控制均无显著差异,非诺贝特组第52周胰岛素原/C肽比值更高。结论不支持使用非诺贝特保存新诊断1型糖尿病患者的β细胞功能。

要点

  • 非诺贝特160 mg每日口服52周,对新诊断1型糖尿病患者2小时C肽水平与安慰剂无显著差异。
  • 非诺贝特组第52周胰岛素原/C肽比值高于安慰剂组,提示β细胞应激标志物未改善。
  • 52周干预不良事件少,无严重不良事件;体外实验显示非诺贝特对人胰岛有应激诱导效应。

核心结论

  • 与临床前研究显示的非诺贝特有益效应相反,这项纵向、随机、安慰剂对照试验不支持使用非诺贝特保存新诊断1型糖尿病患者的β细胞功能。

研究设计与样本

  • 2期、安慰剂对照、双盲、随机临床试验,纳入58例16至40岁新诊断1型糖尿病患者,按1:1比例区组随机(区组大小4)接受非诺贝特160 mg每日口服或安慰剂治疗52周。
  • 主要结局为治疗52周后混合餐耐量试验2小时C肽水平AUC变化;次要结局包括HbA1c和连续血糖监测评估的血糖控制、每日胰岛素用量及胰岛素原/C肽比值。
  • 在治疗前及治疗4、12、26和52周后评估结局指标;参与者、医疗提供者及所有处理结局样本和评估的工作人员均保持盲法。
  • 主要结局统计分析纳入56例参与者(非诺贝特组n=27,2例退出后;安慰剂组n=29)。

主要发现

  • 治疗52周后,两组2小时C肽水平无显著差异(平均差异0.08 nmol/l [95% CI -0.05, 0.23]),胰岛素用量或血糖控制亦无显著差异。
  • 非诺贝特组第52周胰岛素原/C肽比值高于安慰剂组(平均差异0.024 [95% CI 0.000, 0.048],p<0.05)。
  • 血脂质组学分析显示,与安慰剂相比,非诺贝特在第52周抑制了鞘脂代谢和信号传导相关通路。
  • 52周干预引起的不良事件少,无严重不良事件。
  • 在人胰腺胰岛的随访体外实验中,非诺贝特显示出应激诱导效应。

临床怎么用

  • 原文结论指出,这项纵向、随机、安慰剂对照试验不支持使用非诺贝特保存新诊断1型糖尿病患者的β细胞功能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, shows some promise in alleviating beta cell stress and preserving beta cell function in preclinical studies of type 1 diabetes. The aim of this phase 2, placebo-controlled, double-blinded, randomised clinical trial was to investigate the efficacy and safety of fenofibrate in adults and adolescents with newly diagnosed type 1 diabetes. METHODS: We enrolled 58 individuals (aged 16 to 40 years old) with newly diagnosed type 1 diabetes and randomised them to daily oral treatment with fenofibrate 160 mg or placebo for 52 weeks (in a block design with a block size of 4, assigned in a 1:1 ratio). Our primary outcome was change in beta cell function after 52 weeks of treatment, assessed by AUC for C-peptide levels following a 2 h mixed-meal tolerance test. Secondary outcomes included glycaemic control (assessed by HbA1c and continuous glucose monitoring), daily insulin use, and proinsulin/C-peptide (PI/C) ratio as a marker of beta cell stress. We assessed outcome measures before and after 4, 12, 26 and 52 weeks of treatment. Blinding was maintained for participants, their healthcare providers and all staff involved in handling outcome samples and assessment. RESULTS: The statistical analyses for the primary outcome included 56 participants (n=27 in the fenofibrate group, after two withdrawals, and n=29 in the placebo group). We found no significant differences between the groups in either 2 h C-peptide levels (mean difference of 0.08 nmol/l [95% CI -0.05, 0.23]), insulin use or glycaemic control after 52 weeks of treatment. On the contrary, the fenofibrate group showed a higher PI/C ratio at week 52 compared with placebo (mean difference of 0.024 [95% CI 0.000, 0.048], p<0.05). Blood lipidome analysis revealed that fenofibrate repressed pathways involved in sphingolipid metabolism and signalling at week 52 compared with placebo. The 52 week intervention evoked few adverse events and no serious adverse events. Follow-up in vitro experiments in human pancreatic islets demonstrated a stress-inducing effect of fenofibrate. CONCLUSIONS/INTERPRETATION: Contrary to the beneficial effects of fenofibrate found in preclinical studies, this longitudinal, randomised, placebo-controlled trial does not support the use of fenofibrate for preserving beta cell function in individuals with newly diagnosed type 1 diabetes. TRIAL REGISTRATION: EudraCT number: 2019-004434-41 FUNDING: This study was funded by the Sehested Hansens Foundation.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Hostrup PE, Schmidt T, Hellsten SB, et al. Effect of fenofibrate on residual beta cell function in adults and adolescents with newly diagnosed type 1 diabetes: a randomised clinical trial. Diabetologia. 2024. PMID: 39477880. doi:10.1007/s00125-024-06290-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。